The Pasteur Institute has successfully demonstrated inactivation of the Zika Virus using vivoPHIX™:

To determine the ability of vivoPHIX™ to inhibit ZIKV in mosquito tissue sample, ZIKV-infected mosquito midguts were dissected at 6 dpi. Mosquito midguts were then chopped into 3-4 small pieces then transfer into vivoPHIX™. Samples were then treated at 4 degree Celsius for 30 minutes before infectious virus titration by focus forming assay. All of the mosquito in the untreated group were infected with >50,000 FFU/mosquito midgut, while no viable virus particles could be detected in the vivoPHIX™ -treated particles.

‘This is a great development from the Pasteur Institute, and we would like to thank them for sharing this information with us’ said Dr Andrew Goldsborough, Chief Scientific Officer at RNAssist. ‘The RNAssist reagents (vivoPHIX™, genoPHIX™ and virusPHIX™) have all successfully inactivated other viruses, including Dengue West Nile Virus and Influenza and we are pleased to discover that it can inactivate the Zika virus as well. Zika continues to have a devastating effect around the world, and we hope that this inactivation with vivoPHIX™ can play a small part into further research by offering a safer and more efficient way to study the virus.’


Thank you to Natapong Jupatanakul for sharing their results with us.

The Zika virus is a mosquito-borne flavivirus that was first identified in humans in 1952. Outbreaks of Zika virus disease have been recorded in Africa, the Americas, Asia and the Pacific. Whilst most cases of Zika infections do not present any symptoms, some individuals may exhibit mild symptoms for approximately 1 week, such as fever, rash, conjunctivitis, muscle and joint pain, malaise, headache. Zika infection during pregnancy can cause microcephaly and other congenital malformation in infants, as well as increased risk of miscarriage and preterm births. The Zika virus can also increase the risk of neurological conditions in both adults and children, such as Guillain-Barré syndrome, neuropathy and myelitis.

In October 2015, Brazil reported an association between Zika virus infection and microcephaly. Outbreaks and evidence of transmission soon appeared throughout the Americas, Africa, and other regions of the world. To date, a total of 86 countries and territories have reported evidence of mosquito-transmitted Zika infection.

vivoPHIX™, virusPHIX™ and genoPHIX™ reagents, developed by RNAssist are manufactured and distributed by Rapid Labs Ltd. For more information about this range, please click here. If you are interested in working with vivoPHIX™ or our other RNAssist reagents for virus-related studies, please get in touch: rnassist@rapidlabs.co.uk

For Research Use Only – not to be used for diagnostic procedures.